Drug Index

Zanamivir

 
print

Mechanism :

Zanamivir, a sialic acid derivative, potentially inhibits viral neuraminidase of influenza virus, thus altering virus particle aggregation and release. It is active against influenza A and B virus replication.


Indication :

• Treatment and prophylaxis for Influenza A and B.


Contraindications :

Hypersensitivity to zanamivir or any of the components.


Dosing :

Influenza A & B, Prophylaxis:

Household setting, >5 years: 10 mg inhaled once daily for 10 days; initiate within 48 hours of exposure.

Community outbreak, 12-16 years: 10 mg inhaled once daily for 28 days; initiate within 5 days of outbreak.

Influenza A & B, Treatment:

>7 years: 10 mg inhaled every 12 hourly for 5 days. Started within 2 days of symptom onset; administer 2 doses on day 1, at least 2 hours apart.


Adverse Effect :

Nasal symptoms, headache, dizziness, GI disturbances, cough, infection, rash, bronchitis. Rarely, hypersensitivity reactions, arrhythmias, bronchospasm, dyspnoea, facial oedema, seizures and syncope.


Interaction :

Administration of live attenuated influenza vaccine intranasally within 2 weeks before or 48 hr after zanamivir administration improves response to vaccine.


07/14/2019 20:16:47 Zanamivir
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0